Related Experiment Video
Updated: Jul 11, 2026
06:23
Assessment of Plasma Coagulation on Liver Tissue in a Large Animal Model In Vivo
Published on: August 4, 2018
Hypercoagulation and thrombophilia in liver disease
P G Northup1, V Sundaram, M B Fallon
1Division of Gastroenterology and Hepatology, University of Virginia Health System, Charlottesville, VA 22908-0708, USA. pgn5qs@virginia.edu
Journal of Thrombosis and Haemostasis : JTH
|September 26, 2007
Summary
Cirrhosis patients face hypercoagulable events, like thrombosis, despite bleeding risks. More research is needed on diagnostic tests and anticoagulant use in liver disease for better patient outcomes.
Area of Science:
- Hepatology
- Hematology
- Vascular Biology
Background:
- Liver disease disrupts the balance between procoagulant and anticoagulant systems.
- Cirrhosis patients paradoxically experience hypercoagulable events, including thrombosis, alongside bleeding risks.
- These hypercoagulable states contribute to conditions like portal vein thrombosis, pulmonary embolism, and vascular disease in non-alcoholic fatty liver disease.
Purpose of the Study:
- To address critical knowledge gaps in hypercoagulation associated with liver disease.
- To highlight the need for improved diagnostic tools for hypercoagulable risk assessment in cirrhosis.
- To stimulate clinical research on anticoagulant therapies in liver disease patients.
Main Methods:
- Review of an international symposium on coagulation disorders in liver disease.
- Identification of key areas lacking clinical information regarding hypercoagulation.
- Definition of future research directions in the field.
Main Results:
- Hypercoagulable events are a significant, often under-recognized, complication in liver disease, particularly cirrhosis.
- Existing laboratory tests for assessing hypercoagulable risk in cirrhosis are limited and not widely accessible.
- There is a paucity of research on the efficacy and safety of anticoagulants in liver disease patients.
Conclusions:
- Hypercoagulation is a critical aspect of liver disease pathophysiology that requires further investigation.
- Development of practical diagnostic tests and evidence-based anticoagulant strategies is essential for managing liver disease patients.
- Fostering clinical research is crucial to improve the understanding and treatment of coagulation disorders in liver disease.
Related Concept Videos
01:30Anticoagulant Drugs: Low-Molecular-Weight Heparins
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
01:24Disorders of Hemostasis
Hemostasis, the process that stops bleeding after a blood vessel injury, is crucial for maintaining the integrity of the circulatory system. However, disorders of hemostasis can disrupt this delicate balance, leading to either excessive clotting or bleeding. These disorders can be broadly classified into thromboembolic disorders and bleeding disorders.
Thromboembolic Disorders
Two factors primarily cause thromboembolic conditions.
Thromboembolic Disorders
Two factors primarily cause thromboembolic conditions.
01:26Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow
Chronic liver disease significantly impacts drug metabolism due to alterations in hepatic blood flow and enzyme accessibility. This disruption affects the body's pharmacokinetics—the movement and processing of drugs within the system. Key enzymes crucial for metabolizing medications become less accessible, changing how drugs are processed and utilized. Furthermore, liver disease influences the synthesis of plasma proteins, such as albumin and globulins, which play critical roles in drug binding...
01:22Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test
In clinical practice, the direct measurement of hepatic blood flow to evaluate liver function presents significant challenges due to the intricate and specialized nature of the necessary techniques. Consequently, healthcare professionals often rely on empirical estimates derived from thorough patient examinations and liver function tests to gauge liver health. Among the tools at their disposal, the Child–Pugh and MELD scoring systems stand out for their ability to categorize and assess the...
01:24Cirrhosis II: Pathophysiology
Cirrhosis is a progressive chronic liver injury caused by prolonged inflammation, excessive fibrotic remodeling, and impaired regeneration. Over time, repeated hepatic insults disrupt the liver’s architecture and function, leading to reduced blood flow, impaired bile drainage, and diminished metabolic capacity.Pathophysiology of cirrhosisCirrhosis arises from three main responses to chronic liver damage: inflammation, immune activation, and hepatocyte death. These processes lead to structural...
01:27Inflammatory Bowel Disease I: Ulcerative Colitis
Introduction
Inflammatory bowel disease, or IBD, encompasses a group of disorders characterized by chronic inflammation or ulceration of the gastrointestinal tract.
Risk Factors
The exact cause of IBD remains unclear, although it is believed to be due to a mix of genetic, environmental, microbial, and immune factors. Genetic factors are significant in determining susceptibility to IBD, with family history being a critical risk factor. Individuals with a first-degree relative who has IBD are at...
Inflammatory bowel disease, or IBD, encompasses a group of disorders characterized by chronic inflammation or ulceration of the gastrointestinal tract.
Risk Factors
The exact cause of IBD remains unclear, although it is believed to be due to a mix of genetic, environmental, microbial, and immune factors. Genetic factors are significant in determining susceptibility to IBD, with family history being a critical risk factor. Individuals with a first-degree relative who has IBD are at...